Published in Breast Care (Basel) on February 01, 2014
Cardiac risk in the treatment of breast cancer: assessment and management. Breast Cancer (Dove Med Press) (2015) 0.78
Cytochrome P450 pharmacogenetics and cancer. Oncogene (2006) 2.38
Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov (2004) 2.05
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A (2008) 1.76
Mechanisms of non-alcoholic steatohepatitis. Alcohol (2004) 1.66
MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A (2009) 1.53
Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat (2008) 1.40
Pharmacogenetics in breast cancer therapy. Clin Cancer Res (2008) 1.19
Drugs and steatohepatitis. Semin Liver Dis (2002) 1.18
Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer (2009) 1.02
Breast cancer and dietary factors in Taiwanese women. Cancer Causes Control (2005) 0.98
Membrane fatty acids of breast carcinoma: contribution of host fatty acids and tumor properties. Int J Cancer (1995) 0.97
The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat (2005) 0.96
Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab (1998) 0.95
Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Cancer (2005) 0.94
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J (2007) 0.91
The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. Eur J Intern Med (2008) 0.90
Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat (2003) 0.89
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast (2005) 0.87
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer (2007) 0.84
Breast cancer stratification from analysis of micro-array data of micro-dissected specimens. Genome Inform (2007) 0.83
Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients. Clin Chim Acta (2008) 0.82
Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: a null association. Cancer Epidemiol Biomarkers Prev (2008) 0.81
Effect of Coenzyme Q(10), Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles. Breast Cancer Res Treat (2008) 0.81
Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology (2002) 0.80
Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol (2004) 0.78